Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -£1,713 | -£2,226 | -£2,596 | -£1,200 |
| Dep. & Amort. | £105 | £220 | £372 | £751 |
| Deferred Tax | £0 | £0 | -£213 | -£1,396 |
| Stock-Based Comp. | £35 | £86 | £35 | £21 |
| Change in WC | £116 | -£68 | £566 | £127 |
| Other Non-Cash | £93 | £219 | £81 | £1,367 |
| Operating Cash Flow | -£1,364 | -£1,769 | -£1,755 | -£333 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -£10 | -£2 | -£114 | -£258 |
| Net Acquisitions | £0 | £0 | £0 | £0 |
| Inv. Purchases | £0 | £0 | £0 | £0 |
| Inv. Sales/Matur. | £0 | £0 | £0 | £0 |
| Other Inv. Act. | £5 | £3 | £0 | £0 |
| Investing Cash Flow | -£5 | £1 | -£114 | -£258 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -£23 | -£33 | £7 | -£162 |
| Stock Issued | £555 | £2,808 | £0 | £116 |
| Stock Repurch. | £0 | £0 | £0 | £0 |
| Dividends Paid | £0 | £0 | £0 | £0 |
| Other Fin. Act. | -£3 | -£5 | £0 | £0 |
| Financing Cash Flow | £529 | £2,770 | £7 | -£46 |
| Forex Effect | £0 | £2 | £8 | £5 |
| Net Chg. in Cash | -£840 | £1,004 | -£1,854 | -£637 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | £1,199 | £195 | £2,049 | £2,686 |
| End Cash | £359 | £1,199 | £195 | £2,049 |
| Free Cash Flow | -£1,374 | -£1,771 | -£1,869 | -£591 |